The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells
Open accessAbstract
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we able to inhibit tumor growth, but we markedly inhibited the generation and recruitment of myeloid-derived suppressor cells (MDSCs). Targeting tumor glutamine metabolism led to a decrease in CSF3 and hence recruitment of MDSCs as well as immunogenic cell death, leading to an increase in inflammatory tumor-associated macrophages (TAMs). Alternatively, inhibiting glutamine metabolism of the MDSCs themselves led to activation-induced cell death and conversion of MDSCs to inflammatory macrophages. Surprisingly, blocking glutamine metabolism also inhibited IDO expression of both the tumor and myeloid-derived cells, leading to a marked decrease in kynurenine levels. This in turn inhibited the development of metastasis and further enhanced antitumor immunity. Indeed, targeting glutamine metabolism rendered checkpoint blockade-resistant tumors susceptible to immunotherapy. Overall, our studies define an intimate interplay between the unique metabolism of tumors and the metabolism of suppressive immune cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a prodrug of 6‐diazo‐5‐oxo‐l‐norleucine (DON) that blocks glutamine metabolism in myeloid precursor cells can differentiate monocytes into anti‐tumor TAMs, leading to tumor regression in mouse models [56].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
Tang, Z., Li, C., Kang, B., Gao, G., Li, C., & Zhang, Z. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx247 · Cited by 9,849
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“Yet, in spite of these successes it is clear that not all cancers respond to checkpoint blockade alone and even amongst responsive cancers, not all patients respond (52, 60-62).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundUnderstanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“Such an environment favors the residency of suppressive myeloid cells such as MDSCs, TANs, and TAMs, all of which contribute to promoting tumor growth, angiogenesis, metastasis, and immune escape (51).”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 1×
“Alternatively, suppressive immune cells, that are metabolically distinct from effector cells, thrive in the TME (1-3).”
BackgroundPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
BackgroundTumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033 · cited 1×
“Macrophages, which constitute a major component of tumors, are involved in cancer initiation, progression, angiogenesis, metastasis, and creating an immune suppressive environment (4-7).”
Background
Cited by
Macrophages as tools and targets in cancer therapy
Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807
Targeting cancer metabolism in the era of precision oncology
Stine, Z. E., Schug, Z. T., Salvino, J. M., & Dang, C. V. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00339-6 · Cited by 1,189
Cell-programmed nutrient partitioning in the tumour microenvironment
Reinfeld, B. I., Madden, M. Z., Wolf, M. M., Chytil, A., Bader, J. E., Patterson, A. R., Sugiura, A., Cohen, A. S., Ali, A., Do, B. T., et al. (2021) · Nature · doi:10.1038/s41586-021-03442-1 · Cited by 1,023
Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy
Bader, J. E., Voss, K., & Rathmell, J. C. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.05.034 · Cited by 1,030
“reduced MDSC recruitment and promoted their conversion to inflammatory M1 like macrophages (Oh et al., 2020).”
BackgroundThe complex role of tumor-infiltrating macrophages
Christofides, A., Strauss, L., Yeo, A., Cao, C., Charest, A., & Boussiotis, V. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01267-2 · Cited by 849
Metadata
- Authors
- Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., Englert, J. M., Arwood, M. L., Wen, J., Chan-Li, Y., Tenora, L., Majer, P., Rais, R., Slusher, B. S., Horton, M. R., & Powell, J. D.
- Affiliations
- Johns Hopkins University (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- UPMC Enterprises (United States) (US)
- Czech Academy of Sciences, Institute of Organic Chemistry and Biochemistry (CZ)
- Corresponding author
- Powell, Jonathan D.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2020-06-15
- Volume
- 130
- Issue
- 7
- Pages
- 3865-3884
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W3020598614
- Cited by
- 456
- References
- 66
- Citations by year
- 2026: 72 · 2025: 86 · 2024: 77 · 2023: 89 · 2022: 65 · 2021: 49 · 2020: 18
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIH Office of the Director (R01CA229451, S10 OD016374, R01HL141490, R01AI077610, R01CA226765)
- Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University (N/A)
- Under Armour Women’s Health & Breast Cancer Innovation Grants (N/A)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- glutamine metabolism, myeloid-derived suppressor cells, tumor microenvironment, tumor-associated macrophages, immunogenic cell death, granulocyte colony-stimulating factor, IDO, kynurenine, immunometabolism, metastasis, antitumor immunity, small molecule inhibitors
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Female, Glutamine, Immunity, Cellular, Immunotherapy, Macrophages, Male, Mice, Inbred BALB C, Neoplasms, Experimental, Mice, Knockout, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. https://app.cochat.ai/papers/10.1172/jci131859
- The paper
- Oh, M.-H., Sun, I.-H., Zhao, L., Leone, R. D., Sun, I.-M., Xu, W., Collins, S. L., Tam, A. J., Blosser, R. L., Patel, C. H., Englert, J. M., Arwood, M. L., Wen, J., Chan-Li, Y., Tenora, L., Majer, P., Rais, R., Slusher, B. S., Horton, M. R., & Powell, J. D. (2020). Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci131859
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.